13F Holdings
中文EN

NVNO enVVeno Medical Corp

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1661053 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY29.2%
TTM EPS YoY67.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-67.1%
ROA-60.0%
ROIC (approx.)-61.4%
Asset turnover—

Leverage & solvency

Liabilities / assets13.3%
Debt / equity0.00x
Current ratio7.35x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.86x
Accruals ratio-8.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$9.98M$12.25M$13.58M$9.91M$5.73M
SG&A expense$10.92M$11.58M$11.65M$15.02M$11.16M
Operating income-$20.90M-$23.83M-$25.24M-$24.93M-$16.89M
Pretax income-$19.47M-$21.82M———
Net income-$19.47M-$21.82M-$23.52M-$24.67M-$16.53M
EBITDA-$20.76M-$23.64M-$25.02M-$24.72M-$16.74M
EPS (basic)-33.06-44.53-1.91-2.20-1.90
EPS (diluted)-33.06-44.53-1.91-2.20-1.90
Weighted avg. shares (diluted)589,000490,00012.30M11.23M8.68M
Banking
Net interest income———$161,000$19,000
Balance sheet
Cash & equivalents$3.06M$1.75M$3.62M$4.55M$54.73M
Short-term investments$25.15M$41.40M$42.79M$34.49M—
Current assets$28.83M$43.73M$46.92M$39.44M$55.04M
PP&E, net$51,000$182,000$334,000$521,000$618,000
Total assets$29.56M$44.95M$48.63M$41.66M$57.70M
Current liabilities$2.12M$2.10M$1.37M$1.53M$1.58M
Total liabilities$2.43M$2.79M$2.44M$2.93M$3.29M
Shareholders' equity$27.13M$42.16M$46.20M$38.73M$54.40M
Shares outstanding656,000501,00013.32M9.47M9.47M
Cash flow statement
Operating cash flow-$15.57M-$16.84M-$18.86M-$15.62M-$11.85M
Capital expenditure$5,000$37,000$33,000$115,000$368,000
Free cash flow-$15.57M-$16.88M-$18.89M-$15.73M-$12.22M
Investing cash flow$15.86M$1.33M-$7.87M-$34.55M-$368,000
Financing cash flow$1.02M$13.64M$25.79M—$57.61M
Depreciation & amortization$136,000$189,000$220,000$212,000$149,000
Stock-based compensation$3.42M$4.14M$5.20M$8.99M$6.00M

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.